Finding 397723 (2023-001)

Significant Deficiency
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-05-17
Audit: 306580
Organization: Atcc Global & Subsidiaries (VA)
Auditor: Bdo USA PC

AI Summary

  • Core Issue: Approximately $1.3 million in expenditures for a federal grant were not included in the Schedule of Expenditures, leading to potential compliance issues.
  • Impacted Requirements: The failure to follow internal controls for preparing the Schedule violates the Uniform Guidance requirements for accurate reporting of federal awards.
  • Recommended Follow-Up: Strengthen internal controls to ensure timely and accurate reporting of all expenditures to maintain compliance and provide assurance of fair presentation.

Finding Text

2023-001 Internal Controls Over Compliance and Compliance with Reporting - Preparation of the Schedule of Expenditures of Federal Awards Information on the Major Federal Program - Federal Agency: Department of Health and Human Services Assistance Listing Number: 93.855 Assistance Listing Name: Research and Development Cluster Award Number: 1G20AI174721-01 Award Period: 09/16/2022 – 02/29/2024 Criteria: The Uniform Guidance in 2 CFR Section 200.510 (b) states in part: “The auditee must also prepare a schedule of expenditures of Federal awards for the period covered by the auditee’s financial statements which must include the total Federal awards expended as determined in accordance with 2 CFR Section 200.502 Basis for determining Federal awards expended.” The Schedule must provide total Federal awards expended for each individual Federal program. Condition: Expenditures for a grant under the Department of Health and Human Services program of approximately $1.3 million were incurred in 2023, but improperly not included in the Schedule. These expenditures were incurred but not billed to the federal awarding agency at December 31, 2023. Cause: The internal controls established for the review and reconciliation of the Schedule to the underlying accounting records were not consistently followed to ensure accurate reporting of expenditures to the Schedule. Questioned Costs: None. Context: We reviewed the Schedule and found the exception as noted in the condition. Effect: Failure to properly review and support expenditures reported in the Schedule can result in inaccurate reporting and non-compliance with laws and regulations. Repeat Finding: This is not a repeat finding. Recommendation: Internal controls should be designed to prevent, detect and correct errors and/or omissions in a timely manner. Without adequate controls, the Organization cannot provide reasonable assurance that the Schedule is fairly presented. See management’s response for further details.

Corrective Action Plan

Prior to submitting the SEFA each year, a Staff Accountant in ATCC’s Finance & Accounting team will prepare the SEFA, it will be reviewed and approved by ATCC’s Federal Solutions Finance team and the CFO/Controller for completeness, accuracy, and compliance with CFR Section 200.510(b), confirm consistency with the trial balance, and correct any inconsistencies prior to submitting the SEFA report.

Categories

Reporting

Other Findings in this Audit

  • 974165 2023-001
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.RD Influenza Reagent Resource (2) $23.02M
93.RD Microbiology and Infectious Diseases Biological Resource Repository $20.96M
93.RD Central Repository - Pass-Through Award $8.53M
93.RD Reagent Program for Hiv and Other Infectious Diseases $3.60M
93.RD Biological and Emerging Infections Research Resources Program $3.29M
93.855 High Containment Facility Renovations – Pandemic Preparedness $2.27M
93.360 Barda Bsip Idiq $1.44M
93.RD In Vitro Assessment of Antimicrobial Activity $932,873
10.001 Nbaf-Biorepository Transfer Support – Direct Award $838,144
93.RD Molecular Epidemiology Assay Support – Direct Award $158,170
12.351 Early Growth Response Factor 1 Regulation of Neuronal Survival Inflammation – Pass-Through Award $126,938
93.RD Comprehensive and Rapid Response Research Program $122,052
93.RD Labskin Model Data Acquisition – Direct Award $72,138
93.RD Stabilizing Flavivirus Rna Gentegra $35,075
12.351 Genome-Wide Mapping of Host Proteome – Direct Award $18,235
93.855 Generation of Mutants of Mycobacterium Tuberculosis $13,233